Physician profile
Nortei Dowuona
NPI 1154579696
$6,079.94
in general payments reported to CMS, 2019-2025
26 companies · $879 in 2025
The $879 reported for 2025 was more than what 94% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $388 · 2021: $1,124 · 2022: $1,099 · 2023: $785 · 2024: $1,078 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,742.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,169.87 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $763.31 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $639.64 | 2019-2024 | Xarelto |
| Abbvie INC. | $544.59 | 2022-2025 | Dalvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.08 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $443.46 | 2020-2024 | Lokelma, Farxiga |
| Merck Sharp & Dohme LLC | $426.89 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $281.50 | 2019-2024 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.12 | 2023-2025 | Xifaxan |
| Gilead Sciences, INC. | $171.58 | 2021-2024 | |
| Sk Life Science, INC. | $159.81 | 2025 | |
| Alexion Pharmaceuticals, INC. | $153.86 | 2019-2025 | Ultomiris |
| Boston Scientific Corporation | $128.95 | 2019-2024 | Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $85.72 | 2019 | |
| Paratek Pharmaceuticals, INC. | $70.70 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $68.91 | 2023-2024 | Ozempic, Rybelsus |
| Melinta Therapeutics, LLC | $56.72 | 2021-2022 | |
| Amgen INC. | $56.07 | 2019-2024 | Repatha |
| Electromed, INC. | $27.18 | 2023 | Smartvest |
| Abbott Laboratories | $24.94 | 2024 | Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.07 | 2025 | Lifevest |
| Cmp Pharma, INC. | $24.05 | 2021 | |
| Bioxcel Therapeutics, INC. | $23.10 | 2023 | Igalmi |
| Bayer Healthcare Pharmaceuticals INC. | $21.20 | 2024 | |
| Philips North America LLC | $14.20 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nortei Dowuona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.